CONTEXT THERAPEUTICS INC. (CNTX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
10/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCNTX / S&P -78.85% / 15.20% |
LoseCNTX / S&P CNTX unavailable / 15.00% |
LoseCNTX / S&P 33.33% / 50.40% |
| 2026-Q12/3 |
WinCNTX / S&P 78.23% / -4.33% |
LoseCNTX / S&P CNTX unavailable / 11.30% |
WinCNTX / S&P 35.48% / 27.70% |
| 2025-Q41/3 |
WinCNTX / S&P 51.70% / 2.65% |
LoseCNTX / S&P CNTX unavailable / 9.00% |
LoseCNTX / S&P -22.45% / 13.40% |
| 2025-Q31/3 |
WinCNTX / S&P 47.94% / 8.12% |
LoseCNTX / S&P CNTX unavailable / 4.61% |
LoseCNTX / S&P -73.63% / 13.45% |
| 2025-Q20/3 |
LoseCNTX / S&P 7.03% / 10.94% |
LoseCNTX / S&P CNTX unavailable / 4.83% |
LoseCNTX / S&P -66.04% / 10.63% |
| 2025-Q10/3 |
LoseCNTX / S&P -41.71% / -4.27% |
LoseCNTX / S&P CNTX unavailable / 4.98% |
LoseCNTX / S&P -76.69% / 10.57% |
| 2024-Q40/3 |
LoseCNTX / S&P -46.43% / 2.41% |
LoseCNTX / S&P CNTX unavailable / 5.25% |
LoseCNTX / S&P -67.33% / 6.15% |
| 2024-Q30/3 |
LoseCNTX / S&P -2.24% / 5.89% |
LoseCNTX / S&P CNTX unavailable / 5.89% |
LoseCNTX / S&P -30.00% / 6.11% |
| 2024-Q21/3 |
WinCNTX / S&P 45.29% / 4.28% |
LoseCNTX / S&P CNTX unavailable / 5.38% |
LoseCNTX / S&P -9.40% / 5.12% |
| 2024-Q12/3 |
WinCNTX / S&P 22.12% / 10.56% |
LoseCNTX / S&P CNTX unavailable / 5.71% |
WinCNTX / S&P 19.82% / 5.59% |
| 2023-Q41/3 |
LoseCNTX / S&P -25.17% / 11.69% |
LoseCNTX / S&P CNTX unavailable / 6.81% |
WinCNTX / S&P 61.29% / 7.78% |
| 2023-Q30/3 |
LoseCNTX / S&P -5.63% / -3.27% |
LoseCNTX / S&P CNTX unavailable / 7.52% |
LoseCNTX / S&P -107.96% / -5.03% |
| 2023-Q21/3 |
WinCNTX / S&P 184.70% / 8.74% |
LoseCNTX / S&P CNTX unavailable / 9.50% |
LoseCNTX / S&P -109.30% / -8.57% |
| 2023-Q10/3 |
LoseCNTX / S&P -13.80% / 7.50% |
LoseCNTX / S&P CNTX unavailable / 10.77% |
LoseCNTX / S&P -17.78% / -15.69% |
| 2022-Q40/3 |
LoseCNTX / S&P -41.26% / 7.56% |
LoseCNTX / S&P CNTX unavailable / 11.88% |
LoseCNTX / S&P -74.73% / -17.99% |
| 2022-Q30/3 |
LoseCNTX / S&P -47.64% / -4.88% |
LoseCNTX / S&P CNTX unavailable / 13.47% |
LoseCNTX / S&P -176.57% / -1.41% |
| 2022-Q21/3 |
WinCNTX / S&P -2.30% / -16.10% |
LoseCNTX / S&P CNTX unavailable / 13.71% |
LoseCNTX / S&P -163.34% / 11.04% |
| 2022-Q10/3 |
LoseCNTX / S&P -18.42% / -4.60% |
LoseCNTX / S&P CNTX unavailable / 15.97% |
LoseCNTX / S&P CNTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseCNTX / S&P CNTX unavailable / 11.03% |
LoseCNTX / S&P CNTX unavailable / 15.00% |
LoseCNTX / S&P CNTX unavailable / 96.40% |
| 2021-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 0.58% |
LoseCNTX / S&P CNTX unavailable / 10.77% |
LoseCNTX / S&P CNTX unavailable / 69.42% |
| 2021-Q20/3 |
LoseCNTX / S&P CNTX unavailable / 8.55% |
LoseCNTX / S&P CNTX unavailable / 6.58% |
LoseCNTX / S&P CNTX unavailable / 51.81% |
| 2021-Q10/3 |
LoseCNTX / S&P CNTX unavailable / 6.17% |
LoseCNTX / S&P CNTX unavailable / -1.06% |
LoseCNTX / S&P CNTX unavailable / 7.39% |
| 2020-Q40/3 |
LoseCNTX / S&P CNTX unavailable / 12.15% |
LoseCNTX / S&P CNTX unavailable / -3.72% |
LoseCNTX / S&P CNTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 8.93% |
LoseCNTX / S&P CNTX unavailable / -2.04% |
LoseCNTX / S&P CNTX unavailable / -27.10% |
| 2020-Q20/3 |
LoseCNTX / S&P CNTX unavailable / 20.54% |
LoseCNTX / S&P CNTX unavailable / -0.46% |
LoseCNTX / S&P CNTX unavailable / -27.11% |
| 2020-Q10/3 |
LoseCNTX / S&P CNTX unavailable / -19.60% |
LoseCNTX / S&P CNTX unavailable / 3.47% |
LoseCNTX / S&P CNTX unavailable / -14.75% |
| 2019-Q40/3 |
LoseCNTX / S&P CNTX unavailable / 9.07% |
LoseCNTX / S&P CNTX unavailable / 5.36% |
LoseCNTX / S&P CNTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 1.70% |
LoseCNTX / S&P CNTX unavailable / 5.02% |
LoseCNTX / S&P CNTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseCNTX / S&P CNTX unavailable / 4.30% |
LoseCNTX / S&P CNTX unavailable / 6.64% |
LoseCNTX / S&P CNTX unavailable / 8.65% |
| 2019-Q10/3 |
LoseCNTX / S&P CNTX unavailable / 13.65% |
LoseCNTX / S&P CNTX unavailable / 8.12% |
LoseCNTX / S&P CNTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseCNTX / S&P CNTX unavailable / -13.52% |
LoseCNTX / S&P CNTX unavailable / 9.05% |
LoseCNTX / S&P CNTX unavailable / 18.23% |
| 2018-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 7.71% |
LoseCNTX / S&P CNTX unavailable / 10.21% |
LoseCNTX / S&P CNTX unavailable / 19.06% |
| 2018-Q20/3 |
LoseCNTX / S&P CNTX unavailable / 3.43% |
LoseCNTX / S&P CNTX unavailable / 9.03% |
LoseCNTX / S&P CNTX unavailable / 14.46% |
| 2018-Q10/3 |
LoseCNTX / S&P CNTX unavailable / -0.76% |
LoseCNTX / S&P CNTX unavailable / 7.68% |
LoseCNTX / S&P CNTX unavailable / 12.46% |
| 2017-Q40/3 |
LoseCNTX / S&P CNTX unavailable / 6.64% |
LoseCNTX / S&P CNTX unavailable / 7.03% |
LoseCNTX / S&P CNTX unavailable / 13.82% |
| 2017-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 4.48% |
LoseCNTX / S&P CNTX unavailable / 5.68% |
LoseCNTX / S&P CNTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseCNTX / S&P CNTX unavailable / 3.09% |
LoseCNTX / S&P CNTX unavailable / 4.83% |
LoseCNTX / S&P CNTX unavailable / 17.74% |
| 2017-Q10/3 |
LoseCNTX / S&P CNTX unavailable / 6.07% |
LoseCNTX / S&P CNTX unavailable / 3.67% |
LoseCNTX / S&P CNTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseCNTX / S&P CNTX unavailable / 3.82% |
LoseCNTX / S&P CNTX unavailable / 2.09% |
LoseCNTX / S&P CNTX unavailable / 7.05% |
| 2016-Q30/3 |
LoseCNTX / S&P CNTX unavailable / 3.85% |
LoseCNTX / S&P CNTX unavailable / 0.20% |
LoseCNTX / S&P CNTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CNTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.48% | 20.78% |
| Annualized return | -50.48% | 20.78% |
5Y · 2021-10-20 to 2026-08-27
| Metric | CNTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.84% | 83.14% |
| Annualized return | -39.42% | 12.86% |
10Y · 2021-10-20 to 2026-08-27
| Metric | CNTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.84% | 319.30% |
| Annualized return | -22.17% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |